The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9017
Abstract: 9017Background: Although SCLC is highly responsive to initial therapy, most pts relapse < 1 y. Topotecan (T) and irinotecan (I) are used in 2LT of SCLC; however, treatment response is low: ≤10-25% ... read more here.
Keywords: disialoganglioside gd2; sclc; anti disialoganglioside; treatment ... See more keywords
Spinal nerve roots contrast enhancement following anti-GD2 antibody therapy in neuroblastoma
Sign Up to like & getrecommendations! Published in 2018 at "Neurology"
DOI: 10.1212/wnl.0000000000005483
Abstract: A 2-year-old boy with grade IV neuroblastoma presented with acute neurogenic bladder and hyposthenia after 2 weeks of treatment with anti-ganglioside-GD2 antibody (GD2-Ab). Spinal MRI findings are shown in the figure. On nerve conduction studies,… read more here.
Keywords: anti gd2; contrast enhancement; gd2 antibody; spinal nerve ... See more keywords
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16409
Abstract: Background/Aim: Using the tyrosine hydroxylase (TH)-MYCN mouse neuroblastoma (NB) model, we have previously reported the accumulation of mouse mesenchymal stem cells (mMSCs) on tumors in vivo and the antitumor effect of mMSCs transfected with a… read more here.
Keywords: gd2; gd2 mscs; anti gd2; gd2 antibody ... See more keywords